Screener
Intellia Therapeutics NTLA Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.
The source filing: Intellia Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337952
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $106,128 | $155,464 |
| Marketable securities | 331,631 | 294,420 |
| Accounts receivable | 7,321 | 9,468 |
| Prepaid expenses and other current assets | 82,752 | 68,359 |
| Total current assets | 527,832 | 527,711 |
| Marketable securities - noncurrent | 190,595 | 155,250 |
Item 1. Financial Statements
FAQ
- What is Intellia Therapeutics's short-term investments?
- Intellia Therapeutics (NTLA) reported short-term investments of $331.63M in Q2 2026.
- How has Intellia Therapeutics's short-term investments changed year-over-year?
- Intellia Therapeutics's short-term investments increased by 9.3% year-over-year, from $303.48M to $331.63M.
- What is the long-term trend for Intellia Therapeutics's short-term investments?
- Over 5 years (2020 to 2025), Intellia Therapeutics's short-term investments has grown at a -7.6% compound annual growth rate (CAGR), from $437.35M to $294.42M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Intellia Therapeutics's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude